Back to feed
CNBC
CNBC
6/13/2026
The Next Phase Of The Obesity Drug Race

The Next Phase Of The Obesity Drug Race

Short summary

Five years after Wegovy's FDA approval, the obesity drug market has evolved with new GLP-1 pills from Novo Nordisk and Eli Lilly entering in 2026. Competition is intensifying as smaller players like Structure Therapeutics and Zealand Pharma fight for market share. The crowded space signals continued innovation but tighter margins ahead.

  • •GLP-1 oral pills launched by major pharma companies in 2026, expanding beyond Wegovy
  • •Competitive landscape intensifying with smaller biotech firms entering the market
  • •Market growth signals high innovation but crowded competitive environment

Generated with AI, which can make mistakes.

#market-trend#industry-adoption#product-launch
Read full article at CNBC

Is this a good recommendation for you?

Comments

Failed to load comments. Please try again.

Explore more

Health Plan Coverage of GLP-1s – Is a Simple Weight Loss Exclusion Enough?
National Law Review
The economic effects of GLP-1s
Marginal Revolution
FDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters
National Law Review
The original headline is: "This New Medicare Pilot Program Offers GLP-1s For $50 A Month. Here's What You Need To Know"
CNBC